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Abstract Fidaxomicin, an RNA polymerase inhibitor, is being developed by Opti-
mer and Par Pharmaceuticals as a narrow-spectrum antibacterial for the
treatment of Clostridium difficile infections. It is currently in phase III de-
velopment with promising results so far. This review looks at the develop-
ment history and scientific profile of this drug to date.
1. Introduction
Fidaxomicin is an oral, narrow-spectrum anti-
bacterial that is being developed by Optimer
Pharmaceuticals for the treatment of Clostridium
difficile infections. The compound was previously
being jointly developed by Optimer and Par
Pharmaceuticals; the latter had exclusive rights to
fidaxomicin in the US and Canada, but this
agreement has been terminated. Fidaxomicin, an
RNA polymerase inhibitor, is proposed to ad-
dress the growing clinical problem of Clostridium
difficile-associated diarrhea (CDAD). It is a
naturally occurring 18-membered macrocycle,
which is derived from the fermentation of Dacty-
losporangium aurantiacum subspecies hamdenesis.
The product is undergoing phase III development
for CDAD in the US and the EU, and phase I
development in the US as prophylaxis for CDAD
and vancomycin-resistant enterococcal (VRE)
infections.
Antibacterial disturbance of normal anaerobic
gut flora allows the overgrowth of toxigenic
strains of C. difficile and the production of toxins
A and B by this strain. Reactions to these toxins
can result in lesions and severe damage to the
epithelial lining of the colon. C. difficile accounts
for approximately 20% of cases of antibacterial-
associated diarrhea and the majority of cases
of antibacterial-associated colitis. The active
metabolite of fidaxomicin, OP 1118, selectively
targets C. difficile to a similar degree as vanco-
mycin, limiting its impact on the normal in-
testinal flora.
Optimer believes that fidaxomicin may have
some advantages relative to established agents
for the treatment of C. difficile infections, in-
cluding demonstrated activity against C. difficile
(including the hypervirulent strain NAP1/027), a
low rate of drug resistance in C. difficile, minimal
systemic exposure, a twice daily dosing regimen
and minimal effect on normal gut flora.
Optimer is seeking collaborative partners to
commercialize its programs.
1.1 Company Agreements
Par Pharmaceuticals entered into a joint de-
velopment agreement with Optimer for fidax-
omicin (as PAR 101) in May 2005. However, in
February 2007, Par returned all marketing rights
for the product to Optimer. Optimer paid a ter-
mination fee of $US20 million to Par, as it was
Optimer’s decision to terminate the agreement.
Under the terms of the previous collaboration,
Par had the exclusive rights to market, sell and
distribute the product in the US and Canada.
Under the terms of the termination agreement,
Par will receive royalties on future global pro-
duct sales in addition to upfront and milestone
payments.[1-4]
Optimer has an arrangement with Biocon for
manufacture of the active pharmaceutical in-
gredient of fidaxomicin tablets.
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1.2 Key Development Milestones
1.2.1 Clostridium difficile-Associated Diarrhea
(CDAD)
Optimer Pharmaceuticals reported in March
2009 that it was beginning preparations to file a
Marketing Authorisation Application (MAA)
with the European Medicines Agency for oral
administration of fidaxomicin to treat C. difficile
infection. The filing is based on results of the first
phase III trial.[5] Positive results have been re-
ported from the second phase III trial of fidax-
omicin and Optimer plans to use data from this
trial to support a New Drug Application (NDA)
submission in the US in the second half of 2010.[6]
In a multicenter, randomized, double-blind
trial (NCT00314951), the efficacy and safety of a
10-day course of oral fidaxomicin (200mg every
12 h) was compared with that of oral vancomycin
(125mg every 6 h) in 629 patients with C. difficile
infection. Cured patients were followed up for a
subsequent 4-week period to evaluate recurrence.
Results from this trial were favorable.[7-11] The
trial had been initiated as a phase IIb/III trial in
May 2006 in the US; approximately 100 patients
with CDAD were enrolled in the initial phase IIb
trial. Following a positive recommendation from
the Independent Data Safety Monitoring Board
(DSMB) and the US FDA’s agreement with this
decision, Optimer advanced fidaxomicin into the
phase III portion of the trial. The company also
increased the number of study sites in order to
meet the targeted patient enrollment. Enrollment
for this first pivotal phase III trial was completed
in July 2008. A second pivotal phase III trial
(NCT00468728), having an identical design as the
first, was initiated in the US and the EU in 2007,
and completed patient enrollment in November
2009. This trial enrolled a total of 536 patients.
Data reported in February 2010 showed that the
trial met its primary endpoint of non-inferiority
of fidaxomicin to vancomycin. The drug was well
tolerated in the study.[6,12-14]
Fidaxomicin completed proof-of-principle
phase IIa trials for CDAD; fast track status has
been granted by the FDA for this indication.
Preliminary results showed that fidaxomicin
appeared to be efficacious in patients with
CDAD.[3,15] The FDA also selected fidaxomicin
for participation in a Continuous Marketing
Applications (CMA) Pilot 2 Program; this was to
include continuous FDA feedback that was de-
signed to streamline the development process.
The US National Institute of Allergy and In-
fectious Diseases (NIAID) is sponsoring an in-
itiative to find a new treatment for CDAD and
has awarded Optimer a grant to fund the project.
The $US1 million grant is renewable each year
until August 2010 to a maximum of $US3 million
over a 3-year funding period. The award will al-
low the examination of the gut flora as a supple-
mentary study to the ongoing fidaxomicin trials,
in order to confirm narrow spectrum activity and
potency of the agent against hypervirulent epi-
demic CDAD strains. Funds will also be used
to conduct additional toxicology and microbio-
logical studies, as well as a surveillance study of
C. difficile isolates across North America to
compare the activity of fidaxomicin with existing
agents. The NIAID previously awarded the
company a grant to progress development of the
agent in October 2005.[16,17]
During 2005, Optimer secured $US34.2 mil-
lion in financing, which was to be used for further
development of fidaxomicin for this indication in
the North American market.[18]
Results from phase Ib and phase IIa studies in
CDAD were reported in December 2005. The
phase Ib study was designed to evaluate the
pharmacokinetics, tolerance and safety of fidax-
omicin in healthy volunteers. The phase IIa study
was conducted in order to select an appropriate
dose for further clinical development.[19]
Optimer Pharmaceuticals is also developing
an oral suspension formulation to complement
the existing tablet form of fidaxomicin. The sus-
pension formulation is for use in intensive care
unit and elderly patients. The oral suspension for-
mulation is in the preclinical stage of development.
1.2.2 CDAD Prophylaxis
Fidaxomicin is being developed for the pre-
vention of CDAD and Optimer is continuing to
evaluate the design of a proof-of-concept trial in
high-risk populations. Phase I development is
ongoing.
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1.2.3 Vancomycin-Resistant Enterococcal Infection
Prevention
Phase I trials for the prophylaxis (prevention)
of VRE infections have been completed. Subject
to results of an analysis of the propensity of
vancomycin and fidaxomicin to promote VRE
colonization in a completed phase III trial in C.
difficile infection, Optimer will assess whether it
will conduct a clinical trial for the prevention of
VRE infection.
1.2.4 Other Indications
Optimer is also developing fidaxomicin for the
prophylaxis of meticillin-resistant Staphylococcus
aureus (MRSA) infections. Preclinical develop-
ment is ongoing in this indication.
1.3 Patent Information
In April 2009, Optimer was issued a US pro-
duction patent (no. 7 507 564), covering the steps
used in the manufacture of fidaxomicin.[20]
In May 2008, Optimer was issued a US patent
entitled Polymorphic Crystalline Forms of Tiacu-
micin B (no. 7 378 508). This patent covers the
Form A polymorph of the active ingredient in
fidaxomicin, as well as all dosage forms and
pharmaceutical compositions.[21]
Optimer received a Notice of Allowance on a
US patent application in April 2008. The pending
patent covers the polymorphic form of the active
ingredient and once issued, is expected to provide
protection until 2025.[22]
In its Form 10-Q (filed on 5 November 2008),
Optimer reported that it has filed several patent
applications with the US Patent and Trademark
Office, including an application for a composi-




Results from a phase III study have shown
that there was minimal systemic absorption of
fidaxomicin in patients with C. difficile infection,
with all post-dose plasma concentrations being in
the nanogram range. At the same time, the aver-
age fecal drug concentrations were >5000 times
the 90% minimum inhibitory concentration
(MIC90) of fidaxomicin against C. difficile. These
results indicated that fidaxomicin has a favor-
able pharmacokinetic profile for the treatment of
C. difficile infections. Plasma samples were col-
lected predose and 3–5 hours postdose at the start
and end of therapy (EOT; ~day 10), and stool
samples were collected within 24 hours of the
last dose. Postdose samples were available for
168 patients on day 1 and 61 patients at EOT.
Plasma concentrations of fidaxomicin were
<50 ng/mL (i.e. <0.05 mg/mL) in 90% and 87% of
patients on day 1 and EOT, respectively. Mean
fecal levels were 1225 – 759 mg/g (range <0.05–
4640 mg/g) for fidaxomicin and 809 – 651 mg/g
(range <0.05–4170 mg/g) for the metabolite OP
1118 that is formed in the bowel.[8,23]
Following oral administration in a phase I
study, plasma concentrations of fidaxomicin
were generally low, with most falling below the
limit of quantification. However, there appeared
to be dose-related increase in plasma concentra-
tions for fidaxomicin. In the 450mg dose group,
fidaxomicin exhibited a plasma half-life of
0.94–2.77 hours. In the 200 and 300mg doses of
fidaxomicin, high fecal concentrations were ob-
served, with peak levels being between 80 and
435mg/g. In this single-dose, double-blind, placebo-
controlled study, 16 volunteers in two groups were
given two different, escalating doses (100/300mg or
200/450mg) of fidaxomicin or placebo.[24]
Absorption of fidaxomicin was minimal, with
the majority of the drug being eliminated in the
feces, after oral administration at a dosage of
150, 300 or 450mg/day for 10 days. Plasma and
urinary concentrations of fidaxomicin were gen-
erally £5 ng/mL (below the lower limit of quan-
tification) and the mean fecal concentration of
fidaxomicin was high at 916 mg/g.[25]
2.1.2 Preclinical Studies
In Sprague-Dawley rats, the 50% lethal dose
of intravenous fidaxomicin was approximately
200mg/kg. Following an intravenous dose of
20mg/kg, fidaxomicin was cleared from rat plasma
within 10 minutes, with the maximum concen-
tration (Cmax) being between 2 and 7 mg/mL.
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Following oral administration of fidaxomicin in
monkeys, the Cmax in plasma after doses of




Phase III: In a pivotal phase III trial involving
629 patients with CDAD, fidaxomicin was well
tolerated.[10] The incidence of adverse events
(AEs) and serious AEs was similar between the
fidaxomicin- and vancomycin-treated groups.[9]
These results were confirmed by review of
safety reports from 320 fidaxomicin recipients
and 323 vancomycin recipients. Plasma samples
from 183 patients were analyzed for levels of fi-
daxomicin and OP 1118 (major metabolite in the
gastrointestinal [GI] tract). There were no signif-
icant differences in rates of among AEs and
serious AEs between the fidaxomicin and vanco-
mycin arms. Any treatment-emergent AE was
reported in 62.3% and 60.4% in the fidaxomicin
and vancomycin arms, respectively. In the fidax-
omicin and vancomycin arms, GI disorders were
the most common (25.0% vs 22.3%) followed by
general disorders (fever, chills, edema, fatigue;
15.3% vs 16.7%) and infections (urinary tract,
pneumonia; 21.3% vs 19.5%). All-cause mortal-
ity was 5.3% with fidaxomicin and 6.5% for
vancomycin.[8,27]
2.2.2 Healthy Subjects
Fidaxomicin (150, 300 or 450mg/day for 10
days) was not associated with any treatment-
related AEs in 24 healthy volunteers in a phase Ib
double-blinded, placebo-controlled study.[25]
In a phase I study, fidaxomicin was well tol-
erated after single oral doses of up to 450mg,
with no serious AEs being reported. In this single-
dose, double-blind, placebo-controlled study,
Table I. Features and properties
Alternate names Difimicin; Lipiarmycin; OPT 80; OPT-80; PAR 101; PAR-101
Originator Optimer Pharmaceuticals
Highest development phase III (Canada, EU, US)
Active development-indications Clostridium infections, Methicillin-resistant Staphylococcus aureus infections, Vancomycin-resistant
enterococcal infections
Class Glycosides
Mechanism of action DNA-directed RNA polymerase inhibitors
Chemical name (3E,5E,8S,9E,11S,12R,13E,15E,18S)-3-({ [6-deoxy-4-O-(3,5-dichloro-2-ethyl-4,6- dihydroxybenzoyl)-
2-O-methyl-b-D-mannopyranosyl] oxy}methyl)-12-{ [6-deoxy-5-C-methyl-4-O-(2-methylpropanoyl)-b-D-
lyxo-hexopyranosyl] oxy}-11-ethyl-8-hydroxy-18- [(1R)-1-hydroxyethyl] -9,13,15-
trimethyloxacyclooctadeca-3,5,9,13,15-pentaen-2-one
Molecular formula C52 H74 Cl2 O18
CAS registry number 873857-62-6
Route of administration PO
Pharmacodynamics Reduces counts of Clostridium difficile and has minimal effect on native anaerobic fecal flora in vivo
Antimicrobial activity Active against all Gram-positive organisms, especially clostridia; selectivity for C. difficile similar to
vancomycin; equally efficacious against hypervirulent and non-hypervirulent strains of C. difficile
ATC codes
WHO ATC code J01 (antibacterials for systemic use), J01X (other antibacterials)
EphMRA ATC code J1 (systemic antibacterials), J1X (other antibacterials)
Pharmacokinetics
Route of elimination Fecal
t (1/2) beta (h) 0.94–2.77 (Adult)
Adverse events
Most frequent Gastrointestinal disorders, infections
Occasional Signs, symptoms and ill-defined conditions
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16 volunteers in two groups were given two differ-
ent, escalating doses (100/300mg or 200/450mg)
of fidaxomicin or placebo.[24]
2.2.3 Animal Toxicology
No treatment-related effects were observed
when rats were administered an oral dose of
Table II. History
Date Comment
10 February 2010 inThought analysis for Clostridium infections updated
5 February 2010 Efficacy data from a phase III trial in Clostridium infections released by Optimer Pharmaceuticals[6]
31 October 2009 Efficacy data from a phase III trial in Clostridium infections presented at the 47th Annual Meeting of the Infectious
Diseases Society of America (IDSA-2009)[7,32-34]
15 September 2009 Efficacy, adverse events, pharmacokinetic & antimicrobial activity data from a phase III trial in Clostridium infections
presented at the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-
2009)[8,23,27,30,36]
2 June 2009 Efficacy data from a subgroup analysis of a phase III trial in Clostridium infections presented at the Digestive Disease
Week 2009 (DDW-2009)[37]
17 May 2009 Efficacy and adverse events data from a subgroup analysis of a phase III trial inClostridium infections presented at the
19th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID-2009)[9]
11 November 2008 Final efficacy and adverse events data from a phase III trial in Clostridium difficile-associated diarrhea released by
Optimer Pharmaceuticals[10]
24 July 2008 Optimer Pharmaceuticals completes enrollment in the first of its two pivotal phase III trials for Clostridium infections
27 June 2008 Antimicrobial data from a phase IIa trial in Clostridium infections released by Optimer Pharmaceuticals[15]
27 June 2008 Preclinical trials in Clostridium infections in the US (PO, suspension)
8 January 2008 Optimer Pharmaceuticals receives federal grant from the US NIAID for development of difimicin in the treatment of
CDAD
21 September 2007 Data presented at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2007)
added to the Bacterial Infections antimicrobial activity section[28]
3 May 2007 Optimer Pharmaceuticals initiates enrollment in its second phase III trial for CDAD in North America and Europe
3 May 2007 Phase III clinical trials in Clostridium infections in Canada (PO)
3 May 2007 Phase III clinical trials in Clostridium infections in Europe (PO)
20 March 2007 Phase I clinical trials in Clostridium infections prevention in the US (PO)
14 March 2007 Phase III clinical trials in Clostridium infections in the US (PO)
2 March 2007 Par Pharmaceutical returns marketing rights for PAR 101 in the US and Canada
2 March 2007 Preclinical trials in meticillin-resistant Staphylococcus aureus infections in the US (PO)
1 May 2006 Par Pharmaceutical has initiated enrollment in a phase IIb trial for Clostridium difficile-associated diarrhea
1 May 2006 Phase II/III clinical trials in Clostridium infections in the US (PO)
3 February 2006 Data presented at the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2005) have
been added to the adverse events, pharmacokinetics, pharmacodynamics and bacterial infections therapeutic trials
sections[19,25,31]
19 October 2005 Phase I clinical trials in Vancomycin-resistant enterococcal infections prevention in the US (PO)
16 May 2005 Optimer Pharmaceuticals and Par Pharmaceutical have entered into an agreement to co-develop PAR 101 in Canada
and the US for Clostridium infections
16 May 2005 PAR 101 has received fast track status for Clostridium infections in the US
30 November 2004 Phase II clinical trials in Clostridium infections in the US (PO)
15 November 2004 Data presented at the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2004) have
been added to the Adverse events, pharmacokinetics and Viral Infections Antimicrobial Activity sections[24,26,29]
17 March 2004 PAR 101 is available for partnering (http://www.optimerpharma.com)
17 March 2004 Phase I clinical trials in Clostridium infections in the US (PO)
29 August 2003 Optimer Pharmaceuticals has filed an IND with the US FDA for the treatment of CDAD
27 November 2002 New profile
27 November 2002 Preclinical trials in Clostridium infections in the US (unspecified route)
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fidaxomicin at £1000mg/kg. In rats and mon-
keys, repeated oral administration of fidax-
omicin, at doses of £90mg/kg, for 28 consecutive




Fidaxomicin showed no difference in MIC
values between BI/NAP1/027 strains and the
non-BI/NAP1/027 strains, compared with me-
tronidazole and vancomycin which showed high
MIC values (lower in vitro efficacy) for the hyper-
virulent strains.[15]
The major metabolite of fidaxomicin, OP
1118, had selective activity against C. difficile in
vitro. The study testedOP 1118 against 32 bacteria
commonly found in the gastrointestinal tract. OP
1118 showed selectivity for C. difficile over the
other pathogens similar to vancomycin.[28]
In vitro studies have shown fidaxomicin to be
active against all Gram-positive organisms,
especially clostridia, where it inhibited C. difficile
at an MIC value of £0.25 mg/mL.[29]
Analysis of fecal specimens from patients
enrolled in a phase III trial of fidaxomicin have
shown that there was no relationship between the
MIC of baseline clinical isolates and clinical
outcome. No resistance to either fidaxomicin or
vancomycin developed during the study. MIC90
values were generally low (0.25 mg/mL for fidax-
omicin and 2mg/mL for vancomycin). Further-
more, two of the C. difficile strain typing groups
(i.e. BI and K group strains) had lower suscept-
ibilities than other groups to rifaximin and
metronidazole, with resistance to rifaximin oc-
curring in 14% of the BI group and 18% in the K
group. A 10-day course of oral fidaxomicin
(200mg twice daily) was compared with vanco-
mycin (125mg four times daily) in 629 adult
patients (548 evaluable) with C. difficile infection
in a phase III randomized, double-blind trial
conducted in North America.[8,30]
2.4 Pharmacodynamics
2.4.1 Bacterial Infections
In a phase IIa study, fidaxomicin at dosages of
50, 100, or 200mg twice daily for 10 days ap-
peared to selectively reduce counts of C. difficile
without significantly reducing counts of Bacter-
oides (anaerobic fecal flora). This compared
favorably in comparison to treatment with
vancomycin 125mg four times daily for 10 days,
which severely impaired Bacteroides counts.[31]
2.5 Therapeutic Trials
2.5.1 Bacterial Infections
Phase III: A phase III trial met its primary
endpoint of non-inferiority, with 91.7% of fidax-
omicin recipients achieving clinical cure, com-
pared with 90.6% in vancomycin recipients.
Compared with vancomycin, fidaxomicin treat-
ment resulted in lower recurrence rates (12.8% vs
25.3%), and higher global cure rates (79.6% vs
65.5%) [p = 0.002]. The trial enrolled 535 subjects
and those with confirmed C. difficile infections
(CDI) received either fidaxomicin (200mg every
12 hours) or vancomycin (125mg every 6 hours)
for 10 days.[6]
In a pivotal phase III clinical trial, 92.1% of
patients with CDI receiving fidaxomicin achieved
clinical cure, compared with 89.8% of patients
receiving vancomycin. 13.3% of patients treated
with fidaxomicin experienced a recurrence com-
pared with 24.0% with vancomycin; the differ-
ence was significant (p = 0.004). Patients receiving
fidaxomicin had a global cure rate of 77.7%,
compared with 67.1% in patients receiving van-
comycin. In this trial, 629 subjects withC. difficile
infections were randomized to receive either
Table III. Forecasts
InThought Probability of Approval
Indication Approval Date Estimate inThought Approvability Index Last Update
Clostridium infections 1 Nov 2010 75% 10 Feb 2010
Vancomycin-resistant enterococcal infections 31% 27 Jul 2009
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200mg fidaxomicin orally twice daily or 125mg
vancomycin orally four times daily.[5,10] Analysis
of data from this trial (596/629 patients were in
the modified intent-to-treat [mITT] population
and 548/629 in the per protocol [PP] group),
showed the significant correlation between age
and albumin with clinical cure (CC), recurrence
and global cure (GC) rates (p £ 0.09). Disease se-
verity (leukocytosis/fever) correlated with CC
and GC rates but not with the recurrence rate.[32]
Fidaxomicin was associated with a faster time to
resolution of diarrhea than vancomycin (79 hours
vs 105 hours; p = 0.056).[7] At 60 hours after start
of therapy, more patients in the fidaxomicin
group were free of diarrhea than in the vanco-
mycin group (mITT: 63.1% vs 57.6%; p = 0.052
and PP: 67.6% vs 61.5%; p = 0.038).[33] In this
same trial, 20% of subjects with CDI received
concomitant antibiotics and analysis of data
showed that in this group, those treated with fi-
daxomicin versus vancomycin had a significantly
improved GC rate (72% vs 50%; p = 0.022), lower
CDI recurrence rate (23% vs 40%; p= 0.061), and
higher CC rate (87% vs 77%; p = 0.171). Con-
comitant antibiotics during CDI treatment sig-
nificantly decreased CC and increased recurrence
rates.[34]
PP analysis of 432 patients with C. difficile-
associated diarrhea confirmed these previous
data that fidaxomicin was associated with a sig-
nificantly lower infection recurrence rate than
vancomycin (28/211 [13%] vs 53/221 [24%]
patients; p< 0.01). Fidaxomicin was also asso-
ciated with a significantly later onset of recurrent
infection than vancomycin (3% vs 14% recur-
rence within 10 days and 9% vs 20% recurrence
within 20 days after therapy; both p < 0.01).
Patients received oral fidaxomicin (200mg twice
daily) or oral vancomycin (125mg four times
daily) for 10 days.[8,35]
Strain typing results from this phase III trial
showed that the overall cure rate among patients
with hypervirulent BI isolates (also known as
NAP1 by PFGE and 027 by PCR ribotyping) was
significantly lower than patients with non-BI
strains (85.4% vs 95.5%; p = 0.04). C. difficile was
isolated from stools of patients with diarrhea
enrolled in the phase III treatment trial of fidax-
omicin versus vancomycin. Restriction endo-
nuclease analysis (REA) typing was performed
on 184 fidaxomicin and 198 vancomycin isolates
from the baseline and recurrence stools of 70% of
patients. PP findings were presented; mITT
findings were similar. The recurrence rates in the
BI/NAP1/027 group (i.e. 36% of the patients
analyzed), were similar following treatment with
fidaxomicin and vancomycin. In the non-
BI/NAP1/027 groups (64% of the patients ana-
lyzed), patients treated with fidaxomicin had only
a 7.8% (8/103) recurrence rate versus a 25.5%
(27/106) recurrence rate for vancomycin-treated
patients.[8,36]
In a subgroup analysis from the same trial, fi-
daxomicin outperformed vancomycin at a recur-
rence rate endpoint in both outpatient (8.6%,
21.8%) and inpatient (17.9%, 26.1%) settings, as
well as in subjects over the age of 65 years (9.5%,
18.6%) and under the age of 65 years (18.8%,
30.1%). Recurrence rates in the strain type
BI/NAP1/027 subgroup were similar between
agents (25.0%, 24.1%).[9] Additional subgroup
analysis showed that there were lower recurrence
rates for fidaxomicin recipients than for vanco-
mycin recipients with regard to risk factors such
as serum albumin levels, white blood cell (WBC)
count and body temperature (BT), and non-BI
(NAP1/027) strain types. Recurrence rates by
subgroup for fidaxomicin recipients versus van-
comycin recipients were: WBC of <15 000 per mL
and BT of <38C, 10.7% versus 22.4% (17/159 vs
35/156); WBC of 15 000–25 000 per mL or BT of
38–39C, 12.0% versus 20.0% (3/25 vs 6/30);
WBC of >25 000 per mL or BT of >39C, 33.3%
vs 40.0% (1/3 vs 2/5); serum albumin levels of
£25mg/mL, 22.2% versus 31.5% (8/36 vs 17/54);
serum albumin levels of 26–35mg/mL, 10.0%
versus 23.3% (9/90 vs 20/86); strain type non-
BI (NAP1/027), 7.8% versus 25.5% (8/103 vs
27/106).[37]
Phase II: In a phase IIa study, fidaxomicin
therapy (50, 100 or 200mg bid for 10 days) suc-
cessfully treated 41/45 patients (>91% cured
overall) with mild-to-moderate CDAD. Two
patients transferred to conventional therapy. Of
the 41 patients who completed therapy, two
patients (5%) experienced recurrent symptoms
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within the 6-week follow-up. All of the 16 sub-
jects in the top dosing group (200mg twice daily)
achieved clinical cure.[3,15,25]
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